MTPConnect signs MoU with Medical Alley Association
MTPConnect, the Medical Technologies, Biotechnologies and Pharmaceuticals Industry Growth Centre, has signed a memorandum of understanding (MoU) with the Medical Alley Association, a Minnesota-based organisation that enables health innovation and care organisations to successfully influence the evolution of health care.
The MoU was signed at the 2017 MedTech Conference, held last week in San Jose, by MTPConnect General Manager of Stakeholder Engagement Dr Alfredo Martinez-Coll and Medical Alley Association CEO Shaye Mandle. The two organisations seek to increase collaboration on activities that boost the biotechnology, pharmaceutical, health and medical technology sectors of both Australia and the US, planning to work together on activities such as providing introductions and in-market support in their respective jurisdictions, exchanging information on key issues and trends, supporting inbound and outbound missions, and delivering joint events and projects.
“The MedTech Conference … has provided the perfect platform for MTPConnect and Medical Alley to sign an MoU to align our two organisations and collaborate to strengthen the growth of our respective markets,” said Dr Martinez-Coll. “Medical Alley offers outstanding support to Minnesota’s health industry, and we look forward to forging a strong and fruitful relationship, opening further connections between the exciting innovations in our great countries.”
“Australia and Medical Alley have a history dating back to the development of the pacemaker,” added Mandle. “Our partnership today sets the stage for continuing to help patients live better, longer. We look forward to continued partnership with MTPConnect and the Australian medical technology community.”
MTPConnect led a delegation of 29 Australian companies, research organisations and industry bodies to the MedTech Conference to showcase Australia’s innovative medical technology companies and build inroads into international markets. CSIRO and Austrade presented to the international audience in a panel session titled ‘Why Australia’, highlighting Australia’s thriving medical technology, biotechnology and pharmaceutical ecosystem, generous incentive programs, strong credentials in medical devices and diagnostic development, and strong clinical trials sector.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
